BASF's Buyback Ticks Along as Analysts Keep Their Powder Dry
Published on 11/04/2026 at 19:01 | Editorial boerse-global.de
BASF has been quietly retiring its own stock while the sell side stays put. The Ludwigshafen group reported on Monday the repurchase of 355,128 own shares during the October 26–30 window, bringing the total bought back since the programme began on August 3 to 7,595,230 shares through October 30.
That steady drip of buyback disclosures is the least dramatic item in a busy fortnight — but it is also the only one already executed. The rest of BASF's October news flow splits into signed paperwork and signed intentions, and investors are being asked to tell the difference.
A Chinese site, a CO? method, and a closed door at Evonik
On the investment side, BASF inked an agreement with the administration of the Nanjing Jiangbei New Area for a new production site making electronic materials, to be built in the Materials High-Tech Park. Output is scheduled to start by the end of 2028 — a date that gives the project a long runway before it contributes anything to the P&L.
Further back, BASF and Sinopec published joint results on Friday aligning their methods for calculating product carbon footprints, a technical building block rather than a commercial one.
Should investors sell immediately? Or is it worth buying BASF?
The Evonik file is where the door stayed shut. According to Reuters, the Evonik supervisory board on Friday rejected BASF's improved takeover offer of 24 euros per share and resolved not to enter negotiations at all.
The quarter that gave the story its footing
Behind all of it sit the third-quarter figures released on October 28. Sales rose 14% year on year to EUR 16.4 billion, while EBITDA before special items climbed 15% to EUR 1.6 billion.
Those numbers underpin a guidance raise announced roughly a week ago: BASF now expects full-year 2026 EBITDA before special items of EUR 7.4 billion to EUR 7.8 billion, up from a previous range of EUR 6.9 billion to EUR 7.7 billion.
Two banks, two modest moves
Analyst reaction has been restrained rather than rapturous. LBBW lifted its price target to EUR 57 from EUR 56 while keeping a Hold rating, according to media reports — a higher valuation yardstick, not a fresh buy signal, and one offered without a stated rationale. UBS stayed at Neutral with a EUR 55 target on October 29; analyst Joshua Spector revised his estimates after the quarterly report but moved his forecasts only slightly.
The shares gained 2.0% on the day of the LBBW note, though no causal link between the two has been established. What the pair of ratings does suggest is that improved earnings have yet to trigger a broader change in sentiment among analysts.
BASF at a turning point? This analysis reveals what investors need to know now.
What would actually move the needle
For the bullish case to harden, the upgraded guidance needs to be backed by delivery. Concrete operational markers exist: on October 27 BASF started up expanded alkylpolyglucoside capacity in Cincinnati — completed, not merely announced, though no earnings contribution was quantified — and on Friday subsidiary trinamiX and Eurofins Agro Testing unveiled a joint feed-analysis approach combining trinamiX's mobile NIR spectroscopy with the partner's calibration models.
None of these substitutes for proof in the group result. The bearish risk is a fading earnings trajectory that casts doubt on the raised range, and new capacity or cooperation agreements cannot dispel that on their own while their economic contribution stays invisible. A durable re-rating will need further evidence from the income statement — not just a higher target on paper.
Ad
BASF Stock: New Analysis - 4 November
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
